Respiratory and survival outcomes in the year after receiving extracorporeal membrane oxygenation (ECMO) for severe COVID-19 were excellent in a highly selected group treated at one New York City ...
Patients with severe COVID-19 who require venovenous extracorporeal membrane oxygenation (VV-ECMO) support can, if carefully selected and managed, obtain “exceptional survival” approaching 87% at 1 ...
LONDON--(BUSINESS WIRE)--LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced its Bi-Flow Extracorporeal Membrane Oxygenation (ECMO) cannula earned ...
A notable proportion of patients receiving veno-venous extracorporeal membrane oxygenation (ECMO) for acute respiratory failure developed acute kidney injury (AKI), likely due to the greater severity ...
Please provide your email address to receive an email when new articles are posted on . A high effort to eliminate carbon dioxide was linked to a greater likelihood of failing to wean from venovenous ...
The pneumonia presented with the novel coronavirus disease 2019 can lead to severe respiratory failure with profound hypoxemia that requires endotracheal intubation and mechanical ventilation.
Many extracorporeal membrane oxygenation (ECMO) patients experienced long-term neuropsychiatric symptoms, cognitive impairment, or functional impairment, a meta-analysis found. Fully 41% of ECMO ...
Bi-Flow is first bidirectional femoral arterial cannula validated for 29 days’ use LONDON--(BUSINESS WIRE)-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, ...
Bi-Flow is first bidirectional femoral arterial cannula validated for 29 days’ use LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results